康美药业股份有限公司关于收到补偿款的公告

Core Viewpoint - The company has received a compensation amounting to 4.6132 million yuan, which will positively impact its financial results for the fiscal year 2025 [2][3]. Group 1: Compensation Details - The compensation amount received by the company is 4.6132 million yuan [2]. - This compensation will be recognized as a one-time gain in the current financial period, affecting the company's profit for the fiscal year 2025 [4]. - The compensation represents 38.18% of the company's audited net profit for the most recent fiscal year [3]. Group 2: Impact on Financial Statements - According to relevant accounting standards, the compensation will be recorded in the current period's profit and loss statement, leading to a positive impact on the company's 2025 financial results [4]. - The final impact on the company's profit for 2025 will be confirmed by the annual auditing agency [4].